April 16, 2021, 9:02 a.m. EDT

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG"

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Portage Biotech Inc. (PRTG)

or Cancel Already have a watchlist? Log In

Westport, Connecticut, Apr 16, 2021 (Newsfile Corp via COMTEX) -- Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc., /zigman2/quotes/205701577/composite PRTG -1.80% ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE").

Since Portage's Shares began trading on the NASDAQ Capital Market ("Nasdaq") in February 2021, the majority of active trading has shifted to Nasdaq. Simultaneously, the Company has increased operational activity at its U.S. office based in Westport, Connecticut. As a result, Portage's management team and Board of Directors have made the decision to voluntarily delist from the CSE, consolidating the trading of its Shares to Nasdaq.

The CSE delisting will take effect on April 22, 2021. All shareholders can continue trading Portage Shares on Nasdaq under the symbol "PRTG".

About Portage Biotech Inc.

Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive cancers. The Company's access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of the most promising clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage's portfolio consists of five diverse platforms, leveraging delivery by intratumorals, nanoparticles, liposomes, aptamers and virus-like particles. Within these five platforms, Portage has 10 products currently in development with multiple clinical readouts expected over the next 12-24 months. For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc .

Forward-Looking Statements

This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.


Contact: Media@portagebiotech.com

Investor Relations
Chuck Padala

Media Relations
Kate Caruso-Sharpe

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80613


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

copyright (c) newsfile corp. 2021. all rights reserved

US : U.S.: Nasdaq
$ 14.73
-0.27 -1.80%
Volume: 41,120
Nov. 30, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$200.15 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.